Breaking News: Pasithea Therapeutics Reschedules Special Meeting for December 9, 2022 at 9:00 AM Eastern Time

Pasithea Therapeutics Postpones Special Meeting Miami Beach, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) Introduction Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (“CNS”) disorders, announced that it has postponed its Special Stockholder Meeting originally scheduled for November…

Read More

Innovative, Articulate, and Easy to Follow: A Professional Rewrite of Glancy Prongay Murray LLP Reminds Investors of Looming Deadline in Class Action Lawsuit Against Vintage Wine Estates Inc. (VWE)

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vintage Wine Estates, Inc. (VWE) LOS ANGELES, Nov. 28, 2022 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 13, 2023 deadline to file a lead plaintiff motion in the class action filed…

Read More

Get Ready to Say Goodbye to Pain: Double Rainbow Unveils the World’s First Commercial-Scale Biosynthetic Gastrodin – A Natural Pain Reliever with Endless Possibilities!

The global Gastrodin market is expected to rise significantly over the next five years Double Rainbow Announces World’s First Commercial-Scale Biosynthetic Gastrodin, a Natural Marvel Lexington, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) — DoubleRainbow Biosciences (“Double Rainbow”), a sustainable biotech company harnessing bioengineering to improve the quality of human health, today announced the world’s first…

Read More